Clinical trial
A Phase Ⅰ/Ⅲ Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Picankibart in Adolescent Patients With Moderate to Severe Plaque Psoriasis
NCT07265284 is registered in ClinicalTrials.gov with Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase Ⅰ/Ⅲ Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Picankibart in Adolescent Patients With Moderate to Severe Plaque Psoriasis
- Lead sponsor
- Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- December 3, 2025
- Completion date
- January 31, 2029
- Enrollment
- 104 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.